Orangeburg, NY: Radiancy, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted it clearance to market the company's new SPR Clinical Phototherapy System for the treatment of pigmented and vascular lesions.
The new SPR system is the latest advance from Radiancy, featuring the company's proprietary LHE? (light heat energy) technology, where light and heat energy are combined to achieve a variety of therapeutic and aesthetic effects, with no patient downtime and virtually no side effects. Internationally, the LHE technology already holds a leadership position with physicians in the effective treatment of numerous skin conditions, including pigmented and vascular lesions, acne vulgaris, hair removal and psoriasis.
"The FDA clearance of the SPR positions the system for dynamic growth in the US," stated Fabian Tenenbaum, Vice President of Marketing and Sales for Radiancy. "For a relatively low investment, physicians can now enhance their aesthetic practice by providing a new safe and effective phototherapy modality to treat the effects of aging and sun damaged skin."
According to Dr. Gregory Zella, a plastic surgeon in private practice in Largo, FL, "The expanding older patient population in the US is well documented. This has resulted in an increased demand for ways to improve the appearance of skin that over time has been damaged by the sun or other environmental conditions. The new SPR system is an efficient and practical approach to safely and effectively treat photo-aging of the skin, as well as other dermatologic imperfections."
Founded in 1998, Radiancy, Inc., leads the world in developing unique medical products employing its proprietary Light Heat Energy (LHE) technology. The company's mission is to deliver light-based therapeutic systems that improve the lives of people while enhancing clinical practice. Radiancy serves a worldwide clinical community from its headquarters in Orangeburg, N.Y., USA, and from offices in Europe, Asia and Latin America.